Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

被引：85

作者：

Zaja, Francesco ^{[1
]}

Battista, Marta Lisa ^{[1
]}

Pirrotta, Maria Teresa ^{[2
]}

Palmieri, Salvatore ^{[3
]}

Montagna, Michela ^{[4
]}

Vianelli, Nicola ^{[5
]}

Marin, Luciana ^{[1
]}

Cavallin, Margherita ^{[1
]}

Bocchia, Monica ^{[2
]}

Defina, Marzia ^{[2
]}

Ippoliti, Micaela ^{[2
]}

Ferrara, Felicetto ^{[3
]}

Patriarca, Francesca ^{[1
]}

Avanzini, Maria Antonietta ^{[4
]}

Regazzi, Mario ^{[4
]}

Baccarani, Michele ^{[5
]}

Isola, Miriam ^{[6
]}

Soldano, Franca ^{[6
]}

Fanin, Renato ^{[1
]}

机构：

[1] Azienda Osped Univ, DIRM, Clin Ematol, Piazza S Maria della Misericordia, I-33100 Udine, Italy

[2] Policlin Le Scotte, Clin Ematol, Siena, Italy

[3] AORN A Cardarelli, Div Ematol, Naples, Italy

[4] Policlin San Matteo, Fdn IRCCS, Dipartimento Farmacol, Pavia, Italy

[5] Ist Ematol & Oncol Med L&A Seragnoli, Bologna, Italy

[6] Univ Udine, DIRM, Cattedra Stat, Udine, Italy

来源：

HAEMATOLOGICA | 2008年 / 93卷 / 06期

关键词：

immune thrombocytopenia; B-cell depletion; lower dose rituximab;

D O I：

10.3324/haematol.12206

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Rituximab 375 mg/m(2) weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50x10(9)/L) and complete responses (platelet count > 100x10(9)/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose.

引用

页码：930 / 933

页数：4

共 23 条

[1] Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin [J].

Ahmed, A. Razzaque ;

Spigelman, Zachary ;

Cavacini, Lisa A. ;

Posner, Marshall R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (17) :1772-1779

[2] Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura [J].

Arnold, Donald M. ;

Dentali, Francesco ;

Crowther, Mark A. ;

Meyer, Ralph M. ;

Cook, Richard J. ;

Sigouin, Christopher ;

Fraser, Graeme A. ;

Lim, Wendy ;

Kelton, John G. .

ANNALS OF INTERNAL MEDICINE, 2007, 146 (01) :25-W5

[3] Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients [J].

Berentsen, S ;

Ulvestad, E ;

Gjertsen, BT ;

Hjorth-Hansen, H ;

Langholm, R ;

Knutsen, H ;

Ghanima, W ;

Shammas, FV ;

Tjonnfjord, GE .

BLOOD, 2004, 103 (08) :2925-2928

[4]

Braendstrup P, 2003, BLOOD, V102, p298A

[5] Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab [J].

Chemnitz, J ;

Draube, A ;

Scheid, C ;

Staib, P ;

Schulz, A ;

Diehl, V ;

Söhngen, D .

AMERICAN JOURNAL OF HEMATOLOGY, 2002, 71 (02) :105-108

[6] The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura [J].

Cooper, N ;

Stasi, R ;

Cunningham-Rundles, SS ;

Feuerstein, MA ;

Leonard, JP ;

Amadori, S ;

Bussel, JB .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (02) :232-239

[7] Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis [J].

Edwards, JCW ;

Szczepanski, L ;

Szechinski, J ;

Filipowicz-Sosnowska, A ;

Emery, P ;

Close, DR ;

Stevens, RM ;

Shaw, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) :2572-2581

[8] Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis [J].

Garcia-Chavez, Jaime ;

Majluf-Cruz, Abraham ;

Montiel-Cervantes, Laura ;

Esparza, Miriam Garcia-Ruiz ;

Vela-Ojeda, Jorge .

ANNALS OF HEMATOLOGY, 2007, 86 (12) :871-877

[9] Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology [J].

George, JN ;

Woolf, SH ;

Raskob, GE ;

Wasser, JS ;

Aledort, LM ;

Ballem, PJ ;

Blanchette, VS ;

Bussel, JB ;

Cines, DB ;

Kelton, JG ;

Lichtin, AE ;

McMillan, R ;

Okerbloom, JA ;

Regan, DH ;

Warrier, I .

BLOOD, 1996, 88 (01) :3-40

[10] Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab:: a pilot study [J].

Giagounidis, AAN ;

Anhuf, J ;

Schneider, P ;

Germing, U ;

Söhngen, D ;

Quabeck, K ;

Aul, C .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2002, 69 (02) :95-100

← 1 2 3 →